Novartis AG (NVS)

88.12 +0.32  +0.36% NYSE Jul 8, 20:00 Delayed 2m USD

Novartis Free Cash Flow (Quarterly):

2.048B for March 31, 2020
View 4,000+ financial data types
Browse...
View Full Chart

Free Cash Flow (Quarterly) Chart

Export Data
Save Image
Print Image

Historical Free Cash Flow (Quarterly) Data

View and export this data going back to 2000. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2020 2.048B
Dec. 31, 2019 2.904B
Sept. 30, 2019 4.00B
June 30, 2019 2.507B
March 31, 2019 1.957B
Dec. 31, 2018 3.116B
Sept. 30, 2018 3.209B
June 30, 2018 3.459B
March 31, 2018 1.84B
Dec. 31, 2017 2.89B
Sept. 30, 2017 2.917B
June 30, 2017 3.029B
March 31, 2017 1.491B
Dec. 31, 2016 2.81B
Sept. 30, 2016 2.517B
June 30, 2016 2.436B
March 31, 2016 833.00M
Dec. 31, 2015 3.189B
Sept. 30, 2015 2.346B
June 30, 2015 1.868B
March 31, 2015 989.00M
Dec. 31, 2014 4.37B
Sept. 30, 2014 3.012B
June 30, 2014 2.378B
March 31, 2014 733.00M
   
Dec. 31, 2013 3.374B
Sept. 30, 2013 3.50B
June 30, 2013 1.744B
March 31, 2013 1.178B
Dec. 31, 2012 3.948B
Sept. 30, 2012 3.311B
June 30, 2012 2.271B
March 31, 2012 1.892B
Dec. 31, 2011 4.049B
Sept. 30, 2011 3.65B
June 30, 2011 2.822B
March 31, 2011 1.401B
Dec. 31, 2010 3.833B
Sept. 30, 2010 2.835B
June 30, 2010 2.308B
March 31, 2010 2.859B
Dec. 31, 2009 3.472B
Sept. 30, 2009 2.638B
June 30, 2009 1.899B
March 31, 2009 1.449B
Dec. 31, 2008 2.609B
Sept. 30, 2008 2.436B
June 30, 2008 1.071B
March 31, 2008 1.337B
Dec. 31, 2007 1.244B

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

Advertisement

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Benchmarks

Benchmarks
AstraZeneca PLC -237.00M
Gilead Sciences Inc 1.265B
Johnson & Johnson 2.733B

Free Cash Flow (Quarterly) Range, Past 5 Years

Minimum 833.00M Mar 2016
Maximum 4.00B Sep 2019
Average 2.605B
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.